Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Submit a comment

Ouabain-Uninhibited Sodium Transport in Human Erythrocytes. EVIDENCE AGAINST A SECOND PUMP
Michael J. Dunn
Michael J. Dunn
View: Text | PDF
Research Article

Ouabain-Uninhibited Sodium Transport in Human Erythrocytes. EVIDENCE AGAINST A SECOND PUMP

  • Text
  • PDF
Abstract

Others have concluded that a second Na “pump” (active Na outflux) exists in human erythrocytes. This second pump was said to be ouabain-insensitive, unlike the classic ouabain-sensitive Na-K pump. An alternative explanation is that “pump II” is Na exchange diffusion. These hypotheses were examined in the present experiments, utilizing 22Na influx and outflux measurements, net Na fluxes, and ATPase determinations. Ouabain-uninhibited Na outflux was reduced 0.58±0.05 mmol/liter cells per h when extracellular Na (Nao) was replaced by Mg. Ethacrynic acid or furosemide produced similar decrements of outflux (0.50 mmol) in the presence of ouabain and Nao. However, these diuretics had minimal inhibitory effects on outflux in the absence of Nao suggesting that they inhibited principally the Nao-dependent outflux. Whereas this ouabain-uninhibited portion of outflux was dependent on Nao, it was independent of Ko. Contrary to expectations, Na influx did not change when intracellular Na was altered. No uphill, net Na transport (ouabain-uninhibited) could be demonstrated under a variety of circumstances. Furosemide at high concentrations inhibited ATPase, reducing both ouabain-sensitive and ouabain-insensitive enzyme at 1.0 mM concentration while showing no effect on ATPase at 0.05-0.1 mM concentration. The effects of furosemide on ATPase and on Na flux were dissociable on a dose-response curve. Energy depletion for 22 h practically eliminated the Nao-dependent, diuretic-inhibited Na outflux. Activation energies and temperature coefficients for the diuretic-inhibited outflux were one-half the values for the classic ouabain-inhibited pump. These data are interpreted as evidence against a second Na pump. Exchange diffusion accounts adequately for most of these observations; however, the ouabain-insensitive fluxes may be complex and composed of several processes.

Authors

Michael J. Dunn

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts